- call +1-201-465-4211
- email sales@mrinsights.biz
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
Scope of the Report:
This report focuses on the Recombinant Vaccines in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population.
The worldwide market for Recombinant Vaccines is expected to grow at a CAGR of roughly 6.2% over the next five years, will reach 1260 million US$ in 2023, from 880 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Merck & Co., Inc
Green Cross Corporation
Pfizer Inc.
Bayer AG
Sanofi S A.
Protein Science Corporation
GlaxoSmithKline Plc.
Novartis AG
Bharat Biotech
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines
Market Segment by Applications, can be divided into
Recombinant Human Vaccines
Animal Recombinant Vaccines
There are 15 Chapters to deeply display the global Recombinant Vaccines market.
Chapter 1, to describe Recombinant Vaccines Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Recombinant Vaccines, with sales, revenue, and price of Recombinant Vaccines, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Recombinant Vaccines, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Recombinant Vaccines market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Recombinant Vaccines sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Recombinant Vaccines Introduction
1.2 Market Analysis by Type
1.2.1 Subunit Recombinant Vaccines
1.2.2 Attenuated Recombinant Vaccines
1.2.3 Vector Recombinant Vaccines
1.3 Market Analysis by Applications
1.3.1 Recombinant Human Vaccines
1.3.2 Animal Recombinant Vaccines
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Merck & Co., Inc
2.1.1 Business Overview
2.1.2 Recombinant Vaccines Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Merck & Co., Inc Recombinant Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Green Cross Corporation
2.2.1 Business Overview
2.2.2 Recombinant Vaccines Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Green Cross Corporation Recombinant Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Pfizer Inc.
2.3.1 Business Overview
2.3.2 Recombinant Vaccines Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Pfizer Inc. Recombinant Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Bayer AG
2.4.1 Business Overview
2.4.2 Recombinant Vaccines Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Bayer AG Recombinant Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Sanofi S A.
2.5.1 Business Overview
2.5.2 Recombinant Vaccines Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Sanofi S A. Recombinant Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Protein Science Corporation
2.6.1 Business Overview
2.6.2 Recombinant Vaccines Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Protein Science Corporation Recombinant Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 GlaxoSmithKline Plc.
2.7.1 Business Overview
2.7.2 Recombinant Vaccines Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Novartis AG
2.8.1 Business Overview
2.8.2 Recombinant Vaccines Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Novartis AG Recombinant Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Bharat Biotech
2.9.1 Business Overview
2.9.2 Recombinant Vaccines Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Bharat Biotech Recombinant Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Recombinant Vaccines Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Recombinant Vaccines Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Recombinant Vaccines Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Recombinant Vaccines Manufacturer Market Share in 2017
3.3.2 Top 6 Recombinant Vaccines Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Recombinant Vaccines Market Analysis by Regions
4.1 Global Recombinant Vaccines Sales, Revenue and Market Share by Regions
4.1.1 Global Recombinant Vaccines Sales and Market Share by Regions (2013-2018)
4.1.2 Global Recombinant Vaccines Revenue and Market Share by Regions (2013-2018)
4.2 North America Recombinant Vaccines Sales and Growth Rate (2013-2018)
4.3 Europe Recombinant Vaccines Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Recombinant Vaccines Sales and Growth Rate (2013-2018)
4.5 South America Recombinant Vaccines Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Recombinant Vaccines Sales and Growth Rate (2013-2018)
5 North America Recombinant Vaccines by Countries
5.1 North America Recombinant Vaccines Sales, Revenue and Market Share by Countries
5.1.1 North America Recombinant Vaccines Sales and Market Share by Countries (2013-2018)
5.1.2 North America Recombinant Vaccines Revenue and Market Share by Countries (2013-2018)
5.2 United States Recombinant Vaccines Sales and Growth Rate (2013-2018)
5.3 Canada Recombinant Vaccines Sales and Growth Rate (2013-2018)
5.4 Mexico Recombinant Vaccines Sales and Growth Rate (2013-2018)
6 Europe Recombinant Vaccines by Countries
6.1 Europe Recombinant Vaccines Sales, Revenue and Market Share by Countries
6.1.1 Europe Recombinant Vaccines Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Recombinant Vaccines Revenue and Market Share by Countries (2013-2018)
6.2 Germany Recombinant Vaccines Sales and Growth Rate (2013-2018)
6.3 UK Recombinant Vaccines Sales and Growth Rate (2013-2018)
6.4 France Recombinant Vaccines Sales and Growth Rate (2013-2018)
6.5 Russia Recombinant Vaccines Sales and Growth Rate (2013-2018)
6.6 Italy Recombinant Vaccines Sales and Growth Rate (2013-2018)
7 Asia-Pacific Recombinant Vaccines by Countries
7.1 Asia-Pacific Recombinant Vaccines Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Recombinant Vaccines Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Recombinant Vaccines Revenue and Market Share by Countries (2013-2018)
7.2 China Recombinant Vaccines Sales and Growth Rate (2013-2018)
7.3 Japan Recombinant Vaccines Sales and Growth Rate (2013-2018)
7.4 Korea Recombinant Vaccines Sales and Growth Rate (2013-2018)
7.5 India Recombinant Vaccines Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Recombinant Vaccines Sales and Growth Rate (2013-2018)
8 South America Recombinant Vaccines by Countries
8.1 South America Recombinant Vaccines Sales, Revenue and Market Share by Countries
8.1.1 South America Recombinant Vaccines Sales and Market Share by Countries (2013-2018)
8.1.2 South America Recombinant Vaccines Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Recombinant Vaccines Sales and Growth Rate (2013-2018)
8.3 Argentina Recombinant Vaccines Sales and Growth Rate (2013-2018)
8.4 Colombia Recombinant Vaccines Sales and Growth Rate (2013-2018)
9 Middle East and Africa Recombinant Vaccines by Countries
9.1 Middle East and Africa Recombinant Vaccines Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Recombinant Vaccines Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Recombinant Vaccines Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Recombinant Vaccines Sales and Growth Rate (2013-2018)
9.3 UAE Recombinant Vaccines Sales and Growth Rate (2013-2018)
9.4 Egypt Recombinant Vaccines Sales and Growth Rate (2013-2018)
9.5 Nigeria Recombinant Vaccines Sales and Growth Rate (2013-2018)
9.6 South Africa Recombinant Vaccines Sales and Growth Rate (2013-2018)
10 Global Recombinant Vaccines Market Segment by Type
10.1 Global Recombinant Vaccines Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Recombinant Vaccines Sales and Market Share by Type (2013-2018)
10.1.2 Global Recombinant Vaccines Revenue and Market Share by Type (2013-2018)
10.2 Subunit Recombinant Vaccines Sales Growth and Price
10.2.1 Global Subunit Recombinant Vaccines Sales Growth (2013-2018)
10.2.2 Global Subunit Recombinant Vaccines Price (2013-2018)
10.3 Attenuated Recombinant Vaccines Sales Growth and Price
10.3.1 Global Attenuated Recombinant Vaccines Sales Growth (2013-2018)
10.3.2 Global Attenuated Recombinant Vaccines Price (2013-2018)
10.4 Vector Recombinant Vaccines Sales Growth and Price
10.4.1 Global Vector Recombinant Vaccines Sales Growth (2013-2018)
10.4.2 Global Vector Recombinant Vaccines Price (2013-2018)
11 Global Recombinant Vaccines Market Segment by Application
11.1 Global Recombinant Vaccines Sales Market Share by Application (2013-2018)
11.2 Recombinant Human Vaccines Sales Growth (2013-2018)
11.3 Animal Recombinant Vaccines Sales Growth (2013-2018)
12 Recombinant Vaccines Market Forecast (2018-2023)
12.1 Global Recombinant Vaccines Sales, Revenue and Growth Rate (2018-2023)
12.2 Recombinant Vaccines Market Forecast by Regions (2018-2023)
12.2.1 North America Recombinant Vaccines Market Forecast (2018-2023)
12.2.2 Europe Recombinant Vaccines Market Forecast (2018-2023)
12.2.3 Asia-Pacific Recombinant Vaccines Market Forecast (2018-2023)
12.2.4 South America Recombinant Vaccines Market Forecast (2018-2023)
12.2.5 Middle East and Africa Recombinant Vaccines Market Forecast (2018-2023)
12.3 Recombinant Vaccines Market Forecast by Type (2018-2023)
12.3.1 Global Recombinant Vaccines Sales Forecast by Type (2018-2023)
12.3.2 Global Recombinant Vaccines Market Share Forecast by Type (2018-2023)
12.4 Recombinant Vaccines Market Forecast by Application (2018-2023)
12.4.1 Global Recombinant Vaccines Sales Forecast by Application (2018-2023)
12.4.2 Global Recombinant Vaccines Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Recombinant Vaccines Picture
Table Product Specifications of Recombinant Vaccines
Figure Global Sales Market Share of Recombinant Vaccines by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
